Umeclidinium is a prescription antimuscarinic bronchodilator available in the form of an inhaler device. It is used to treat chronic obstructive pulmonary disease (COPD) and is available in ...

Umeclidinium 62.5mcg, vilanterol 25mcg; per ­inhalation; dry pwd for oral inhalation. LABA as monotherapy (without ICS) for asthma can increase risk of asthma-related events. Do not initiate in ...

GSK said in the first quarter of 2024, the sales of Specialty Medicines increased, driven by strong HIV and Oncology ...

Panoro Energy has signed an agreement with the Government of Equatorial Guinea on the key terms for the award of offshore ...

This will remain unchanged with GSK continuing to give Innoviva its cut of sales on Trelegy, Relvar and Anoro respiratory products. Together these products generated sales of almost $2.5 billion ...

and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Breo brought in £41 million in the first three months of the year, while Anoro added another £12 million, unable to offset the approximately £100 million reduction in Seretide/Advair sales in ...

Cash Position: Ended the quarter with $178.36 million in cash and cash equivalents, down from $193.51 million at the end of the previous quarter.

Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and ...

Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva ...